Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up to $20.55

Tyra Biosciences, Inc. (NASDAQ:TYRA) gapped up prior to trading on Monday . The stock had previously closed at $20.55, but opened at $21.24. Tyra Biosciences shares last traded at $21.24, with a volume of 930 shares.

Wall Street Analyst Weigh In

TYRA has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $23.00 price objective on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Wedbush reissued an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Thursday, August 8th. Piper Sandler assumed coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price objective on the stock. Finally, Oppenheimer cut their target price on shares of Tyra Biosciences from $28.00 to $25.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.80.

Tyra Biosciences Trading Up 11.0 %

The firm has a fifty day moving average of $21.00 and a two-hundred day moving average of $18.63. The company has a market capitalization of $1.17 billion, a PE ratio of -13.31 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.09. On average, equities analysts expect that Tyra Biosciences, Inc. will post -1.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

A number of large investors have recently modified their holdings of TYRA. HighVista Strategies LLC purchased a new stake in Tyra Biosciences in the second quarter worth about $257,000. Rhumbline Advisers lifted its stake in shares of Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after purchasing an additional 2,574 shares during the period. Victory Capital Management Inc. boosted its position in shares of Tyra Biosciences by 53.4% during the fourth quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock valued at $696,000 after purchasing an additional 17,490 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Tyra Biosciences by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after purchasing an additional 14,352 shares during the period. Finally, Oppenheimer & Co. Inc. purchased a new position in Tyra Biosciences during the first quarter valued at $977,000. Institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.